To confirm the molecular mechanisms underlying the antimetastatic effects of BRACs, we investigated whether treatment with BRACs inhibited the mRNA expression of raf1, mek, and jnk in HER2+ breast cancer cells. Here, RAF1 is linked to breast cancer.